Related Experiment Videos
Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207
1Department of Physiology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. yazakit@med.keio.ac.jp
Abstract:
Over the last few years, a conditionally replicating herpes simplex virus 1 (HSV-1) vector, G207 has been used for the treatment of several malignant tumors. In this article we evaluate the anti-tumoral effect of G207 against prostate cancer in vitro and in vivo. The susceptibility of the human prostate cancer cell lines, DU145 and PC3 to G207 at a multiplicity of infection (MOI) of 0.1 was examined. In addition, the growth characteristics of G207 were assessed. Athymic mice with s.c. tumors were inoculated in vivo intraneoplastically with 1 x 10(7) plaque-forming units (PFU) of G207. For the pathological analyses, s.c. tumors were stained with X-gal. DU145 and PC3 were efficiently destroyed by G207 within 7 days. The viral yields of G207 increased time-dependently. In vivo, the intraneoplastic inoculation of G207 induced a significant inhibition of the tumor growth. The mean tumor growth ratio was significantly inhibited in the G207-treated tumors (DU145, P < 0.0001; PC3, P < 0.001 versus controls). In a pathological study, many lacZ-positive cells were diffusely present in the G207-treated tumors. G207 showed a significant antitumoral effect against human prostate cancer cell lines, and thus may be considered a useful agent for the treatment of prostate cancer.
Insights
The herpes simplex virus 1 (HSV-1) vector G207 effectively destroyed prostate cancer cells in laboratory tests and significantly inhibited tumor growth in mice. G207 demonstrates potential as a novel therapeutic agent for prostate cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Molecular oncology
- Viral gene therapy
Background:
- Conditionally replicating herpes simplex virus 1 (HSV-1) vector G207 is explored for malignant tumor treatment.
- Prostate cancer remains a significant global health concern requiring novel therapeutic strategies.
Purpose of the Study:
- To evaluate the anti-tumoral efficacy of the G207 vector against human prostate cancer cell lines (DU145, PC3) in vitro.
- To assess the in vivo anti-cancer effects of G207 in a mouse model of prostate cancer.
Main Methods:
- In vitro susceptibility of DU145 and PC3 cells to G207 at a multiplicity of infection (MOI) of 0.1 was determined.
- In vivo studies involved intraneoplastic inoculation of G207 into athymic mice bearing subcutaneous tumors.
- Tumor tissues were stained with X-gal for pathological analysis.
Main Results:
- G207 efficiently destroyed DU145 and PC3 prostate cancer cells within 7 days in vitro.
- G207 viral yields demonstrated time-dependent increases.
- Intraneoplastic G207 inoculation significantly inhibited tumor growth in vivo (DU145, P < 0.0001; PC3, P < 0.001).
- Pathological analysis revealed diffuse lacZ-positive cells in G207-treated tumors.
Conclusions:
- G207 exhibits significant anti-tumoral activity against human prostate cancer cell lines.
- The G207 vector shows promise as a therapeutic agent for prostate cancer treatment.